Sign in
Taking people in United StatesNo phase

Magnetic brain stimulation before bed to help sleep in insomnia research

Tests magnetic brain stimulation against a sham version on sleep in 20 healthy adults.

Key facts

Who runs it
University of Arizona
Where
Tucson, United StatesSee the site
Trial code
Registry title
Transcranial Magnetic Stimulation of the Default Mode Network to Improve Sleep
Status
Recruiting
People taking part
20 people, planned
Started
6 Aug 2021
Planned end
31 Aug 2022
Type of study
Interventional, 2 groups
Treatments tested
  • Active cTBS
  • Sham cTBS
Record updated
17 August 2022

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for otherwise healthy adults with primary insomnia. It tests magnetic brain stimulation (cTBS) against a sham stimulation before sleep.

Age
18 to 50 years
Sex
Men and women. Women cannot be pregnant or breastfeeding.
Disease stage
Primary insomnia, shown by questionnaire scores. You need at least two of three: ISI 15 or more, PSQI 6 or more, ESS 11 or more.
Earlier treatment
You cannot currently take certain medicines, such as Ambien, benzodiazepines, stimulants, antidepressants (SSRIs, SNRIs), antipsychotics, blood pressure or thyroid medicines. You also cannot take sleep supplements such as melatonin, valerian root or kava root.

Main reasons for not taking part

  • Metal implants or medical devices that are unsafe for MRI or TMS, such as pacemakers
  • Sleep apnea or other sleep or breathing disorders (STOP-BANG score of 3 or higher)
  • Past or present heart or brain problems, seizures, or a seizure in a parent, brother or sister
  • Depression or anxiety in the past 2 years, or other mental health problems at any time
  • Night shift work, unusual sleep schedules in the past six months, or travel to another time zone

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Healthy men and non-pregnant, non-lactating women 18-50 (inclusive) years of age, free from contraindicated diseases, medications, devices, and conditions
  • Participants must meet the criteria for primary insomnia as determined by scores on the ISI, PSQI, and ESS. Participants must obtain two out of three of the following required scores for each questionnaire:; Greater than or equal to 15 for ISI (Gagnon, Belanger, Ivers, \& Morin, 2013); Greater than or equal to 6 for PSQI (Buysse et al 1989); Greater than or equal to 11 for ESS (Johns, 2000)

Who cannot take part

  • Travel outside the time zone within the two weeks prior to enrollment visit and at any point while active in the study
  • Self-reported current use of certain prescription medications including Ambien, benzodiazepines, stimulants (amphetamines, medication for narcolepsy), antidepressants (SSRIs, SNRIs), antipsychotics, blood pressure medications, thyroid medications
  • Self-reported or suspected use of illicit drugs (to include but not limited to benzodiazepines, amphetamines, cocaine, opioids)
  • Presence of any metal implant or medical device which may pose a safety risk for MRI or TMS (see below for examples); Cardiac pacemakers; Metal clips on blood vessels (also called stents); Artificial heart valves; Artificial arms, hands, legs, etc; Brain stimulator devices; Implanted drug pumps; Ear implants; Eye implants or known metal fragments in eyes; Exposure to shrapnel or metal filings (wounded in military combat, sheet metal workers, welders, and others); Other metallic surgical hardware in vital areas; Certain tattoos with metallic ink; Certain transdermal (skin) patches such as NicoDerm (nicotine for tobacco dependence), Transderm Scop (scopolamine for motion sickness), or Ortho Evra (birth control)
  • Past or present history of sleep or breathing-related disorders such as sleep apnea (exclusion upon obtaining a score of 3 or higher on the STOP-BANG questionnaire)
  • Self-reported major medical problems including past or present history of heart problems and/or neurological problems (to include but not limited to heart murmur, heart attack, TBI, stroke, tumor, epilepsy or another seizure disorder)
  • Self-reported past or present history of cardiovascular disease (to include but not limited to arrhythmias, valvular heart disease, congestive heart failure, history of sudden cardiac death or myocardial infarction)
  • Self-reported past or present history of neurological disorder (to include but not limited to traumatic brain injury including concussions, strokes, tumors, epilepsy or another seizure disorder, amnesia for any reason, hydrocephalus, multiple sclerosis)
  • Self-reported past or present history of any seizures or seizure disorders
  • Self-reported first-degree family history (like a mother, father, or sibling) of a seizure or seizure disorder
  • Self-reported underlying acute or chronic pulmonary disease requiring daily inhaler use
  • Self-reported history of fainting spells or syncope
  • Self-reported past (at any point in the participant's history) or present psychiatric problems not including depression and/or anxiety disorders (to include but not limited to bipolar, mania, ADHD, or psychotic disorders)
  • Self-reported history of depression and/or anxiety disorders within the past 2 years
  • Failure to cooperate with requirements of the study
  • Learned English past age 3
  • Self-reported suicidal ideation as indicated by a score equal to or greater than 2 on the BDI
  • Self-reported current use of supplements that may affect sleep (to include but not limited to melatonin, valerian root, kava root)
  • Self-reported caffeine use in excess of 300 mg (e.g., approximately 8 caffeinated sodas or approximately 3-4 12-oz cups of coffee) per day on average
  • Self-reported or suspected regular nicotine use (or addiction) (defined as more than 1 cigarette or equivalent per week within the last 1 year)
  • Self-reported or suspected heavy alcohol use (minimum limit to define heavy alcohol use is 14 drinks per week)
  • (Females only) Positive urine pregnancy result (Urine HCG Test results)
  • (Females only) Self-reported or suspected current breast-feeding or collecting breast-milk
  • Speaking English as a non-primary language
  • Less than 9th grade education
  • Unusual sleep schedules in past six months
  • Overnight shift work
  • Inability to read and sign consent

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 50 years old?

Where in United States

  • University of Arizona Psychiatry DepartmentTucson, United StatesContact: William D Killgore, PhDTaking people

About the trial

What the trial wants to find out

Insomnia is generally believed to be caused by excessive arousal of the brain and body. Rather than transitioning normally and quickly from wakefulness to sleep, individuals with insomnia tend to enter into a self-perpetuating cycle of self-referential thought and arousal. Brain imaging research has shown that these same internally focused self-reflective thoughts tend to activate a core system in the brain known as the Default Mode Network (DMN). The DMN is usually active when a person is internally focused, such as during daydreaming or mind wandering, but tends to be deactivated when the brain is focused on the external environment. The investigators hypothesize that excess activation and connectivity of this brain network may perpetuate internal conversations, worry, and rumination, preventing individuals with insomnia from falling asleep quickly and remaining asleep. Therefore, the goal of the present study is to use a brain stimulation technique known as transcranial magnetic stimulation (TMS) to target the DMN and slightly reduce its activation before bed. This should result in an easier time falling asleep.

Read full original descriptionShow less

For this study, the investigators will recruit 20 healthy individuals and have them sleep in the lab on two occasions. On one occasion, they will be stimulated with a type of TMS called continuous theta burst stimulation (cTBS), which will be targeted toward their DMN. They will then try to sleep in the lab while the investigators record their brain waves using a technique known as polysomnography (PSG). On the other occasion, these same individuals will undergo the same procedure, but the TMS machine will be in a deactivated mode to present a "sham" stimulation. Participants will again try to sleep in the lab following the sham treatment while being recorded with PSG. Neither the participants nor the experimenters will know which condition the participant is receiving at the time. This will only be revealed later. Additionally, all participants will receive a brain scan just before and just after the TMS procedures so that the investigators can examine changes in brain connectivity and chemistry. The investigators expect that the participants will sleep better following the cTBS than following the sham condition and that this will be associated with measurable differences in their brain connectivity and brain chemistry.

If effective, this project would have identified an innovative and novel approach for improving sleep without using drugs.

The 2 groups in the trial

  • Active cTBS first, then sham cTBSTreatment being tested

    Participants complete an Enrollment Visit followed by one week of at-home actigraphy. Participants return to the lab for Overnight Visit 1 and undergo a MRI scan followed by active cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep. Participants return home and complete another week of at-home actigraphy. Participants then return to the lab for Overnight Visit 2 where they undergo a MRI scan followed by sham cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep.

    Treatment: Active cTBS and Sham cTBS

  • Sham cTBS first, then active cTBSTreatment being tested

    Participants complete an Enrollment Visit followed by one week of at-home actigraphy. Participants return to the lab for Overnight Visit 1 and undergo a MRI scan followed by sham cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep. Participants return home and complete another week of at-home actigraphy. Participants then return to the lab for Overnight Visit 2 where they undergo a MRI scan followed by active cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep.

    Treatment: Active cTBS and Sham cTBS

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Transcranial Magnetic Stimulation of the Default Mode Network to Improve Sleep
Plain-language title
Magnetic brain stimulation before bed to help sleep in insomnia researchGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT04953559, who can take part
Publications
Record updated
17 August 2022
Transcranial Magnetic Stimulation of the Default Mode Network to Improve Sleep (NCT04953559) – Frontlight Research